Bortezomib Triggers ROS-Driven Mitochondrial Cell Death and Blocks SKP2 Signaling in Skin T-Cell Lymphoma
New research shows the proteasome inhibitor bortezomib kills cutaneous T-cell lymphoma cells through ROS-dependent mitochondrial apoptosis while suppressing the SKP2-p21/p27 ...
